Related references
Note: Only part of the references are listed.Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
Ziyang Yu et al.
CLINICAL CANCER RESEARCH (2014)
Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
Andres Jan Schrader et al.
EUROPEAN UROLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mechanisms of the androgen receptor splicing in prostate cancer cells
L. L. Liu et al.
ONCOGENE (2014)
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y. Loriot et al.
ANNALS OF ONCOLOGY (2013)
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
K. L. Noonan et al.
ANNALS OF ONCOLOGY (2013)
Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
Yingming Li et al.
CANCER RESEARCH (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2012)
Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer
John T. Isaacs et al.
PROSTATE (2012)
Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
Changmeng Cai et al.
CANCER CELL (2011)
Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc
Chih-Pin Chuu et al.
CANCER SCIENCE (2011)
Transcription-Induced DNA Double Strand Breaks: Both Oncogenic Force and Potential Therapeutic Target?
Michael C. Haffner et al.
CLINICAL CANCER RESEARCH (2011)
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Testosterone replacement in prostate cancer survivors with hypogonadal symptoms
Robert L. Leibowitz et al.
BJU INTERNATIONAL (2010)
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
Shihua Sun et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements
Michael C. Haffner et al.
NATURE GENETICS (2010)
Loss of Androgen Receptor-Dependent Growth Suppression by Prostate Cancer Cells Can Occur Independently from Acquiring Oncogenic Addiction to Androgen Receptor Signaling
Jason M. D'Antonio et al.
PLOS ONE (2010)
Bipolar Androgen Therapy: The Rationale for Rapid Cycling of Supraphysiologic Androgen/Ablation in Men With Castration Resistant Prostate Cancer
Samuel R. Denmeade et al.
PROSTATE (2010)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
CANCER RESEARCH (2009)
Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
Rong Hu et al.
CANCER RESEARCH (2009)
DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer
Jason M. D'Antonio et al.
ENDOCRINE-RELATED CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer
Michael J. Morris et al.
EUROPEAN UROLOGY (2009)
A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer
Russell Szmulewitz et al.
EUROPEAN UROLOGY (2009)
Tissue Culture Media Supplemented With 10% Fetal Calf Serum Contains a Castrate Level of Testosterone
J. P. Michiel Sedelaar et al.
PROSTATE (2009)
Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial
P. Mathew
ANNALS OF ONCOLOGY (2008)
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer - Differences from the classic metabolic syndrome
Matthew R. Smith et al.
CANCER (2008)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance
Scott M. Dehm et al.
CANCER RESEARCH (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation
Donald J. Vander Griend et al.
CELL CYCLE (2007)
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells
Ivan V. Litvinov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells
AR Uzgare et al.
CANCER RESEARCH (2004)
Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program
RB Shah et al.
CANCER RESEARCH (2004)
Ras signaling in prostate cancer progression
MJ Weber et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
J Edwards et al.
BRITISH JOURNAL OF CANCER (2003)
Progressive osteoporosis during androgen deprivation therapy for prostate cancer
HW Daniell et al.
JOURNAL OF UROLOGY (2000)
Share Paper
